DUBLIN--(BUSINESS WIRE)--The "Hepatitis Therapeutics Market Size, Share, And Trend Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
- Owing to high prevalence of target disease with subsequently surge in treatment rate HCV, thus hepatitis C therapeutics held the majority market share in 2016
- In 2016, North American region accounted for majority of revenue share of 42.9% owing to high patient awareness levels and the presence of advanced healthcare infrastructure
- However, Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period owing to rapidly increasing healthcare expenditure
- Key players include Gilead, Johnson & Johnson, Merck & Co. Inc., Bristol-Myers Squibb Company and AbbVie Inc.
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Hepatitis Therapeutics Market Variables, Trends & Scope
Chapter 4. Hepatitis Therapeutics Market: Disease Type Estimates & Trend Analysis
Chapter 5. Hepatitis Therapeutics Market: Regional Outlook, By Disease Type
Chapter 6. Competitive Landscape
- Gilead Lifesciences
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
- Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/research/4g9wv7/hepatitis?w=4